Stockscreener 앱 받기
4.93
1.20%
-0.06
시간 외 거래:
4.85
-0.08
-1.62%
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances - MSN
Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger - TipRanks
Traws Pharma Reports Promising Antiviral Drug Progress - TipRanks
Traws Pharma earnings missed by $8.56, revenue topped estimates - Investing.com Canada
Traws Pharma Inc (TRAW) Quarterly 10-Q Report - Quartzy
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - The Manila Times
Traws Pharma Reports Promising Phase 1 Data Despite Widening Q3 Losses | TRAW Stock News - StockTitan
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Marketscreener.com
Traws Pharma regains Nasdaq compliance with bid price - Investing.com India
Traws Pharma regains Nasdaq compliance with bid price By Investing.com - Investing.com UK
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment - StockTitan
Traws Pharma Inc (TRAW) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges Amid ... - Yahoo Finance
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil - MyChesCo
Onconova Therapeutics stock hits 52-week low at $4.87 - Investing.com India
Traws Pharma reports positive Phase 1 flu drug results - Investing.com
Traws Pharma reports positive Phase 1 flu drug results By Investing.com - Investing.com Canada
Traws Pharma announces topline Phase 1 data for tivoxavir marboxil - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewswire
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - Marketscreener.com
Onconova Therapeutics stock hits 52-week low at $4.87 By Investing.com - Investing.com Australia
Traws Pharma announces results from its early stage trial for its COVID candidate - MSN
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate - MSN
Traws Pharma reports promising Phase 1 trial for COVID drug - Investing.com
Traws Pharma announces topline Phase 1 results for ratutrelvir - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor - GlobeNewswire
Traws Pharma faces Nasdaq delisting over bid price issue By Investing.com - Investing.com Canada
Traws Pharma faces Nasdaq delisting over bid price issue - Investing.com India
Onconova Therapeutics stock hits 52-week low at $6 - Investing.com India
Onconova Therapeutics stock hits 52-week low at $6 By Investing.com - Investing.com South Africa
Financial Metrics Check: Traws Pharma Inc. (TRAW)’s Ratios for Trailing Twelve Months - The Dwinnex
Traws Pharma Welcomes Luba Greenwood Amid Strategic Board Changes - MyChesCo
Traws Pharma, Inc. Announces Board Changes - Marketscreener.com
Traws Pharma appoints new director, bids farewell to Marino - Investing.com
Was anything positive for Traws Pharma Inc. (TRAW) stock last session? - US Post News
Traws Pharma Appoints Luba Greenwood to Board of Directors - citybiz
Traws Pharma appoints Luba Greenwood to board of directors - TipRanks
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors - GlobeNewswire
Traws Pharma Announces Key Approvals and Reverse Stock Split at 2024 Special Meeting - MSN
Closing Figures Unveiled: Traws Pharma Inc. (TRAW) Drop -10.26, Closes at 0.31 - The Dwinnex
Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Onconova Therapeutics stock hits 52-week low at $0.32 - Investing.com
Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks
Traws Pharma announces results of 2024 Special Meeting of Stockholders - TipRanks
3.66%
1.11%
자본화:
|
볼륨(24시간):